IGF2BP1—An Oncofetal RNA-Binding Protein Fuels Tumor Virus Propagation

• Published in: Viruses Vol. 15; no. 7; p. 1431
• Main Authors: Glaß, Markus, Hüttelmaier, Stefan
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 24.06.2023; MDPI
• Subjects: Binding proteins; data collection; HBV; HCV; Health aspects; Hepatitis B; Hepatitis C; HIV; HPV; Human immunodeficiency virus; Human papillomavirus; IGF2BP1; Messenger RNA; miRNA; neoplasm progression; neoplasms; Oncogenic viruses; Papillomaviridae; Physiological aspects; Review; RNA viruses; RNA-binding protein; RNA-binding proteins; Severe acute respiratory syndrome coronavirus 2; Tumor viruses; Tumors; Viral infections; virus; Virus research; viruses; Zika virus; Germany; SARS-CoV-2; HIV; IGF2BP1; HCV; HBV; virus; HPV
• ISSN: 1999-4915; 1999-4915
• DOI: 10.3390/v15071431

The oncofetal RNA-binding protein IGF2BP1 has been reported to be a driver of tumor progression in a multitude of cancer entities. Its main function is the stabilization of target transcripts by shielding these from miRNA-mediated degradation. However, there is growing evidence that several virus species recruit IGF2BP1 to promote their propagation. In particular, tumor-promoting viruses, such as hepatitis B/C and human papillomaviruses, benefit from IGF2BP1. Moreover, recent evidence suggests that non-oncogenic viruses, such as SARS-CoV-2, also take advantage of IGF2BP1. The only virus inhibited by IGF2BP1 reported to date is HIV-1. This review summarizes the current knowledge about the interactions between IGF2BP1 and different virus species. It further recapitulates several findings by presenting analyses from publicly available high-throughput datasets.